3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Tumor-Agnostic
1
Gynecologic
1
Genitourinary
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Endometrial Neoplasms
1
Interventions
Paclitaxel
7
pembrolizumab
6
olaparib
5
Carboplatin
4
Bevacizumab
4
tisotumab vedotin
2
niraparib
2
mirvetuximab soravtansine
2
durvalumab
2
defactinib
2
Topotecan
2
Taxes
2
Saline Solution
2
Immunoglobulin G
2
Disulfides
2
Cisplatin
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sodium thiosulfate
1
sapanisertib
1
sacituzumab govitecan
1
rucaparib
1
relatlimab
1
relacorilant
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
lenvatinib
×
Gynecologic
×
Clear all
NCT03517449
2026-03-19
MK-3475-775
Eisai Inc.
Phase 3
Completed
827 enrolled
34 charts
1 FDA